本文已被:浏览 285次 下载 259次
Received:January 07, 2026 Published Online:September 24, 2026
Received:January 07, 2026 Published Online:September 24, 2026
中文摘要: 目的 分析初诊多发性骨髓瘤患者凝血标志物D-二聚体(D-D)与纤维蛋白原(FIB)比值(D-D/FIB 比值)与短期预后之间的关联,并评估其预测效能。方法 回顾性分析2020 年12 月至2023 年12 月苏北人民医院收治的180例初治多发性骨髓瘤患者的临床资料。所有患者均接受规范治疗并完成12个月随访。根据随访结局分为生存组(n=135)与死亡组(n=45)。比较两组临床资料及实验室指标;采用Cox回归分析影响多发性骨髓瘤患者预后的独立因素;采用受试者工作特征(ROC)曲线评估D-D/FIB 比值等指标的预测价值;根据截断值分组后,采用Kaplan-Meier法绘制生存曲线并进行log-rank检验。结果 死亡组国际分期体系(ISS)分期Ⅲ期患者占比、高危染色体异常检出率及D-D水平、D-D/FIB比值均显著高于生存组,FIB水平低于生存组(P<0.05)。Cox回归分析结果显示,高危染色体异常(HR=4.831,95%CI:2.363~9.875,P<0.01)、D-D/FIB 比值高(HR=5.425,95%CI:2.549~11.547,P<0.01)为危险因素;初诊时具备移植适应证(HR=0.401,95%CI:0.161~0.994,P=0.048)为保护因素。ROC曲线分析显示,D-D/FIB比值预测预后的曲线下面积(AUC)为0.831(95%CI:0.768~0.883),优于单独的FIB(AUC=0.755)或D-D 水平(AUC=0.787)(P<0.05)。D-D/FIB 比值的截断值为0.51,其灵敏度为66.67%,特异度为86.67%。根据此截断值将患者分为高比值组(D-D/FIB>0.51,n=48)和低比值组(D-D/FIB≤0.51,n=132)。Kaplan-Meier 分析显示高比值组12 个月累积生存率低于低比值组(37.5% vs 88.6%,log-rank χ2=58.305,P<0.01)。结论 D-D/FIB 比值对多发性骨髓瘤患者12 个月的预后具有良好的预测价值。D-D/FIB 比值可为多发性骨髓瘤患者早期风险分层和预后评估提供参考。
Abstract:Objective To analyze the association between the D-Dimer to fibrinogen(D-D/FIB)ratio and short-term prognosis in newly diagnosed multiple myeloma patients,and evaluate its predictive efficacy. Methods Clinical data from 180 treatment - na?ve patients with multiple myeloma admitted to Northern Jiangsu People 's Hospital between December 2020 and December 2023 were retrospectively analyzed. All patients received standardized treatment and completed 12-month follow-up. Based on outcomes,they were categorized into survival group(n=135)and death group(n=45). Clinical parameters and laboratory indices were compared between two groups. Cox regression was used to identify independent prognostic factors. The predictive value of indicators such as the D-D/FIB ratio was evaluated by receiver operating characteristic(ROC)curve analysis. Kaplan-Meier survival analysis(log-rank test)was performed after stratification by optimal cut-off values. Results Compared with the death group,the proportion of patients with stage Ⅲaccording to the International Staging System (ISS),the detection rate of high - risk chromosomal abnormalities,D-D levels and the D-D/FIB ratio,were all significantly higher than those in the surviving group,while the FIB level was lower than that in the survival group(P<0.05). Cox regression analysis revealed that high-risk chromosomal abnormalities(HR=4.831,95%CI:2.363-9.875,P<0.01)and elevated D-D/FIB ratio(HR=5.425,95%CI:2.549-11.547,P<0.01)were risk factors,while eligibility for transplantation at initial diagnosis(HR=0.401,95%CI:0.161-0.994,P=0.048)was a protective factor. ROC curve analysis showed that the area under the curve (AUC)for predicting prognosis using the D-D/FIB ratio was 0.831(95%CI:0.768-0.883),better than using FIB(AUC=0.755)or D-D levels(AUC=0.787)alone(P<0.05). The optimal cut-off value was 0.51(sensitivity:66.67%,specificity:86.67%).Kaplan-Meier curves confirmed lower 12-month survival in high-ratio versus low-ratio subgroups(37.5% vs 88.6%,log-rank χ2=58.305,P<0.01). Conclusion D-D/FIB ratio effectively predicts 12-month prognosis in patients with multiple myeloma. It provides crucial reference for early risk stratification and outcome assessment.
keywords: Multiple myeloma D-Dimer Fibrinogen D-Dimer to fibrinogen ratio Thrombosis Risk stratification High-risk chromosomal abnormality
文章编号: 中图分类号:R733.3 文献标志码:A
基金项目:扬州市科技计划项目(YZ2023085)
引用文本:
